Serina Therapeutics Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on Serina Therapeutics's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 433.1% |
| Return on equity | 128.2% |
| Net Margin | 167.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Serina Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | 5 | 4 | 0 |
| 30 Sep 23 | 0 | 4 | 2 | 0 |
| 30 Jun 23 | 0 | 1 | 2 | 0 |
| 31 Mar 23 | 0 | -1 | 2 | 0 |
| 31 Dec 22 | 1 | -3 | 1 | 0 |
| 31 Dec 21 | 3 | -1 | 1 | 0 |
Quality Earnings: SER has a large one-off gain of $7.6M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: SER became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SER's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: SER has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SER has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: SER's Return on Equity (128.2%) is considered outstanding.